Bristol-Myers Says Celgene Deal On Track For Q3 Close After Shareholder Approval

Bristol-Myers Squibb (BMY) announced that its shareholders voted to approve the issuance of shares of Bristol-Myers common stock in connection with the company's pending merger with Celgene (CELG). More than 75% of the shares voted at the special meeting were voted in favor of the Celgene merger agreement.

The transaction remains on track to close in Q3 of 2019, subject to regulatory approvals, Bristol-Myers said. "We are pleased with the outcome of today's Special Meeting and thank our shareholders for their support for this combination," said Giovanni Caforio, CEO of Bristol-Myers Squibb. "Together with Celgene, we will create a premier innovative biopharma company with leading scientific capabilities that is well positioned to address the needs of patients through high-value innovative medicines. We look forward to bringing the companies together, which we believe will deliver significant shareholder value".